

ACORDA THERAPEUTICS INC

FORM 8-K (Current report filing)

Filed 01/08/07 for the Period Ending 01/08/07

Address	420 SAW MILL RIVER ROAD ARDSLEY, NY 10502
Telephone	914-347-4300
CIK	0001008848
Symbol	ACOR
SIC Code	2836 - Biological Products, Except Diagnostic Substances
Industry	Biotechnology & Drugs
Sector	Healthcare
Fiscal Year	12/31

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): **January 8, 2007**

Acorda Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

000-50513
(Commission
File Number)

13-3831168
(I.R.S. Employer
Identification No.)

15 Skyline Drive, Hawthorne, NY
(Address of principal executive offices)

10532
(Zip Code)

Registrant's telephone number, including area code: **(914) 347-4300**

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-
-

Item 2.02 Results of Operations and Financial Condition.

On January 8, 2007, the Registrant issued a press release reporting that its shipments of Zanaflex Capsules™ and Zanaflex® tablets to wholesalers for 2006 were approximately \$31 million. Gross sales are based on prescription data, which are not yet available. A copy of the release is attached hereto as Exhibit 99.1 and incorporated by reference into this Item.

Item 8.01 Other Events.

In the press release referenced above in Item 2.02, the Registrant also announced the completion of the previously announced expansion of its sales force, which promotes Zanaflex Capsules™. A copy of the release is attached hereto as Exhibit 99.1 and incorporated by reference into this Item.

The information in this Item 8.01 and in Item 2.02 of Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits

99.1 Press Release dated January 8, 2007

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Acorda Therapeutics, Inc.

January 8, 2007

By /s/ Jane Wasman

Name: Jane Wasman

Title: *Executive Vice President, General
Counsel and Corporate Secretary*

Exhibit Index

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release dated January 8, 2007

**CONTACT:**

Tierney Saccavino
Acorda Therapeutics
(914) 347-4300 ext. 104
tsaccavino@acorda.com

FOR IMMEDIATE RELEASE

Acorda Therapeutics Announces Completion of Zanaflex Capsules(TM) Sales Force Expansion

Hawthorne, NY January 8, 2007 - Acorda Therapeutics, Inc. ® (Nasdaq: ACOR) reported today that it has completed the previously announced expansion of its sales force to 65 people, 52 of whom are area business managers calling on specialist and primary care physicians. The Acorda sales team promotes Zanaflex Capsules (tizanidine hydrochloride).

“I’m pleased that we were able to complete the expansion of the sales force so quickly while maintaining the high quality of the team,” said John Librie, VP, Sales and Marketing. “The new members of Acorda’s sales force have an average of 13 years of biotech and pharmaceutical sales experience and will be a terrific addition to the company.”

For 2005, Acorda reported shipments of Zanaflex Capsules and Zanaflex tablets to wholesalers of \$18.6 million, using its pilot sales force of 14 professionals. In March, the company announced the expansion of its sales force to 32, and 2006 shipments to wholesalers were approximately \$31 million. Gross sales are based on prescription data, which are not yet available.

Forward Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, regarding management’s expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including Acorda Therapeutics’ ability to successfully market and sell Zanaflex Capsules, the risk of unfavorable results from future studies of Fampridine-SR, delays in obtaining or failure to obtain FDA approval of Fampridine-SR, competition, the ability to obtain additional financing to support Acorda Therapeutics’ operations, unfavorable results from its preclinical programs, and failure to protect its intellectual property or to defend against the intellectual property claims of others. These and other risks are described in greater detail in Acorda Therapeutics’ filings with the Securities and Exchange Commission. Acorda Therapeutics may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Acorda Therapeutics disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

About Acorda Therapeutics

Acorda Therapeutics is a biotechnology company developing therapies for SCI, MS and related nervous system disorders. The Company’s marketed products include Zanaflex Capsules (tizanidine hydrochloride), a short-acting drug indicated for the management of spasticity. For full prescribing information, please go to www.zanaflexcapsules.com. Acorda’s lead clinical stage product, Fampridine-SR, recently completed a Phase 3 study in people with MS. The Company’s pipeline includes a number of products in development for the treatment, regeneration and repair of the spinal cord and brain.

###
